Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 9,944 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infectious Clear all

Conditions: Leishmaniasis
Interventions: Miltefosine; Drug
Lead sponsor: Knight Therapeutics (USA) Inc; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Poolesville, Maryland

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Saint Davids, Pennsylvania

Conditions: Vascular Access Complication, Central Line Complication, Central Line-Associated Infection, Superficial Vein Thrombosis, Deep Vein Thrombosis
Interventions: Midline catheter; Device
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 2 more

Conditions: Clostridium Difficile Infection Recurrence
Interventions: Bacillus velezensis DSM 33864, Placebo; Dietary Supplement
Lead sponsor: Novozymes A/S; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Hiv, Substance Use Disorders
Interventions: Descovy 200Mg 25Mg Tablet, PrEP; Drug · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: COVID-19, SARS-CoV2 Infection
Interventions: Polyvinylalcohol strip [diagnostic]; Device
Lead sponsor: Colorado School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 3,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 2 more

Conditions: HIV-1
Interventions: No drug will be administered; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Sacramento, California • Miami, Florida • Atlanta, Georgia + 2 more

Conditions: COVID-19
Interventions: Tocilizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Hepatitis C
Interventions: Pegylated Interferon alfa-2b, Simeprevir, Ribavirin, Sofosbuvir; Drug
Lead sponsor: Center For Hepatitis C, Atlanta, GA; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Vaginal Health
Interventions: estriol, Placebo; Drug
Lead sponsor: Gynuity Health Projects; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Los Angeles, California • Chicago, Illinois

Conditions: HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
Interventions: raltegravir; Drug
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Surgical Site Infection
Interventions: ZuraPrep, ChloraPrep; Drug
Lead sponsor: Zurex Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Sterling, Virginia

Conditions: Pregnancy Related, Cesarean Wound Disruption, Cesarean Section; Infection
Interventions: Application of Autologous Amniotic Fluid; Device
Lead sponsor: Recibio, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Long Haul COVID, Postural Orthostatic Tachycardia Syndrome
Interventions: Ivabradine; Drug
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis B, Chronic
Interventions: AHB-137; Drug
Lead sponsor: AusperBio Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Redwood City, California • Baltimore, Maryland • New York, New York + 1 more

Conditions: Human Immunodeficiency Virus, Substance Related Disorder, Post Traumatic Stress Disorder
Interventions: Neutral Writing, Expressive Writing, Contingency Management; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV, Hepatitis C, Opioid-use Disorder, Injection Drug Use
Interventions: Referral to harm reduction services; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 15 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Carbondale, Illinois • Murphysboro, Illinois

Conditions: Degenerative Disc Disease, Spinal Stenosis, Spondylitis, Spondylolisthesis, Herniated Disk
Interventions: BioBurst Fluid, Burst Allograft; Device
Lead sponsor: Burst Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Carrollton, Georgia • Paducah, Kentucky • Bethesda, Maryland + 1 more

Conditions: HIV-1 Infection
Interventions: Rilpivirine; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 29
States / cities: Beverly Hills, California • Long Beach, California • Los Angeles, California + 26 more

Conditions: Third Degree Burn, Burns, Wound Infection, Degloving Injury
Interventions: StrataGraft Skin Tissue, Cadaver allograft; Biological · Procedure
Lead sponsor: Stratatech, a Mallinckrodt Company; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Phoenix, Arizona • Madison, Wisconsin

Conditions: Papillomavirus Infections
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Wound Infection, Abscess, Systemic Inflammation, Cellulitis
Interventions: Single-Dose IV Oritavancin Diphosphate, IV Vancomycin, Placebo; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 968 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: EVG, Background regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee

Search by objective public record fields.

Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

Novel Strategy to Encourage Early Removal of Central Venous Catheters

A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

PrEP at a Syringe Services Program

Asymptomatic and Pre-symptomatic Transmission of SARS-CoV-2 in a Community Congregant Setting

A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

The SIM-SOF Trial for Hepatitis C

Topical Estriol for Vaginal Health

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™ (ZX-ZP-0055)

The Collection and Application of Autologous Amniotic Fluid At Cesarean Delivery Closure.

Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort

Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

Trauma Intervention for Affect Regulation, AIDS, and Substances

Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)

Burst Biologics Spinal Fusion Registry

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects

High-Risk HPV Infections in Women Aged 25 to 65

Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants